Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 10 | 2024 | 284 | 5.380 |
Why?
|
| Food Hypersensitivity | 2 | 2024 | 98 | 1.620 |
Why?
|
| Medicaid | 2 | 2024 | 252 | 1.500 |
Why?
|
| Conflict of Interest | 2 | 2017 | 25 | 1.100 |
Why?
|
| Food Supply | 2 | 2024 | 90 | 1.030 |
Why?
|
| Hypersensitivity | 4 | 2023 | 75 | 1.000 |
Why?
|
| Allergy and Immunology | 1 | 2024 | 19 | 0.930 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2024 | 29 | 0.880 |
Why?
|
| Dermatitis, Atopic | 1 | 2023 | 34 | 0.860 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2020 | 3 | 0.700 |
Why?
|
| Penicillins | 1 | 2018 | 29 | 0.600 |
Why?
|
| Child | 8 | 2024 | 6906 | 0.590 |
Why?
|
| Drug Hypersensitivity | 1 | 2018 | 38 | 0.580 |
Why?
|
| Financial Support | 1 | 2017 | 3 | 0.560 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 38 | 0.550 |
Why?
|
| Hepatitis C | 1 | 2017 | 80 | 0.510 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 484 | 0.510 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 281 | 0.490 |
Why?
|
| Humans | 18 | 2024 | 50503 | 0.460 |
Why?
|
| Biomedical Research | 1 | 2017 | 244 | 0.450 |
Why?
|
| Arkansas | 3 | 2024 | 1985 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 468 | 0.440 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2014 | 51 | 0.430 |
Why?
|
| United States | 4 | 2024 | 4955 | 0.380 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 226 | 0.350 |
Why?
|
| Hospitalization | 2 | 2024 | 675 | 0.330 |
Why?
|
| Adolescent | 3 | 2024 | 6443 | 0.230 |
Why?
|
| Vitamin D Deficiency | 1 | 2023 | 44 | 0.210 |
Why?
|
| Hospitals | 1 | 2024 | 173 | 0.200 |
Why?
|
| Air Pollution | 1 | 2023 | 46 | 0.200 |
Why?
|
| Air Pollutants | 1 | 2023 | 64 | 0.200 |
Why?
|
| Health Services Accessibility | 2 | 2019 | 424 | 0.200 |
Why?
|
| Poverty | 1 | 2024 | 208 | 0.200 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 591 | 0.180 |
Why?
|
| Phenotype | 1 | 2024 | 739 | 0.180 |
Why?
|
| Patients | 1 | 2021 | 48 | 0.180 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2020 | 7 | 0.180 |
Why?
|
| Racism | 1 | 2022 | 60 | 0.180 |
Why?
|
| Education, Medical | 1 | 2022 | 112 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 266 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2019 | 110 | 0.140 |
Why?
|
| Policy Making | 1 | 2017 | 31 | 0.140 |
Why?
|
| Disclosure | 1 | 2017 | 39 | 0.140 |
Why?
|
| Infant | 1 | 2024 | 3628 | 0.130 |
Why?
|
| Child, Preschool | 1 | 2024 | 3942 | 0.130 |
Why?
|
| Parents | 1 | 2019 | 318 | 0.130 |
Why?
|
| Disease Management | 1 | 2017 | 178 | 0.120 |
Why?
|
| Risk Factors | 1 | 2024 | 3724 | 0.120 |
Why?
|
| Retrospective Studies | 1 | 2024 | 6263 | 0.100 |
Why?
|
| Environmental Exposure | 2 | 2023 | 200 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 303 | 0.090 |
Why?
|
| Young Adult | 1 | 2019 | 4102 | 0.080 |
Why?
|
| Aged | 1 | 2021 | 9741 | 0.070 |
Why?
|
| Prosencephalon | 1 | 2007 | 12 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 134 | 0.070 |
Why?
|
| Dopamine | 1 | 2007 | 175 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 405 | 0.060 |
Why?
|
| Male | 2 | 2024 | 25907 | 0.060 |
Why?
|
| Female | 2 | 2024 | 27081 | 0.060 |
Why?
|
| Cholecalciferol | 1 | 2023 | 22 | 0.060 |
Why?
|
| Vitamins | 1 | 2023 | 63 | 0.050 |
Why?
|
| Vitamin D | 1 | 2023 | 87 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2023 | 136 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 130 | 0.050 |
Why?
|
| Health Promotion | 1 | 2023 | 258 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2023 | 449 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 400 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 2378 | 0.040 |
Why?
|
| Adult | 1 | 2023 | 13577 | 0.020 |
Why?
|
| Oxidopamine | 1 | 2007 | 4 | 0.020 |
Why?
|
| Sympatholytics | 1 | 2007 | 6 | 0.020 |
Why?
|
| Denervation | 1 | 2007 | 20 | 0.020 |
Why?
|
| Reflex | 1 | 2007 | 31 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 2007 | 51 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 296 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2007 | 363 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 572 | 0.020 |
Why?
|
| Motor Activity | 1 | 2007 | 225 | 0.020 |
Why?
|
| Mice | 1 | 2007 | 5687 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 13124 | 0.010 |
Why?
|